Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | UBE2N | P61088 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 6/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21068128 | 0.88 | JAK2 (0.46) | KDM4EUBE2NHTR6L3MBTL1CYP19A1 | |
| SCHEMBL21058468 | 0.87 | HTR6 (0.39) | KDM4EUBE2NHTR6L3MBTL1CYP19A1 | |
| SCHEMBL12011379 | 0.86 | HTR6 (0.45) | KDM4EUBE2NHTR6L3MBTL1PKM | |
| SCHEMBL16968327 | 0.85 | KDM4E (0.37) | KDM4EUBE2NHTR6L3MBTL1CYP19A1 | |
| SCHEMBL18662607 | 0.85 | HTR6 (0.39) | KDM4EUBE2NHTR6L3MBTL1PKM | |
| SCHEMBL28604693 | 0.84 | RAPGEF4 (0.35) | HTR6RAPGEF4JAK2BTK | |
| SCHEMBL10182014 | 0.82 | KDM4E (0.56) | KDM4EUBE2NHTR6L3MBTL1CYP19A1 | |
| SCHEMBL29414046 | 0.82 | KDM4E (0.56) | KDM4EUBE2NHTR6L3MBTL1CYP19A1 | |
| SCHEMBL31395395 | 0.80 | BRD4 (0.41) | KDM4EUBE2NHTR6L3MBTL1PKM | |
| SCHEMBL21870788 | 0.79 | L3MBTL1 (0.35) | KDM4EUBE2NL3MBTL1CYP19A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880671-B1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | HK INNO N CORP (KR) | 2025-03-12 | — | — | EP | disclosed |
| US-12180185-B2 | Compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof | HK INNO.N CORPORATION (KR) | 2024-12-31 | — | — | US | disclosed |
| US-20220009902-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | HK INNO.N CORPORATION (KR) | 2022-01-13 | — | — | US | disclosed |
| EP-3880671-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | HK inno.N Corporation (KR) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020101382-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | HK INNO.N CORPORATION (KR) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12180185-B2 | Compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof | MAP3K20, MAP3K1, MAP3K15 | KDM4E 1696/4885UBE2N 3030/4885HTR6 4253/4885 |
| US-20220009902-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | MAP3K20, MAP3K1, MAP3K15 | KDM4E 1970/4885UBE2N 2901/4885HTR6 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.